Brokerages Set MiNK Therapeutics, Inc. (NASDAQ:INKT) Price Target at $37.50

MiNK Therapeutics, Inc. (NASDAQ:INKT) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $37.50.

A number of analysts recently weighed in on INKT shares. Zacks Research raised shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. Wall Street Zen cut MiNK Therapeutics to a “strong sell” rating in a research note on Saturday, August 23rd. B. Riley raised MiNK Therapeutics to a “strong-buy” rating in a research note on Friday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th. Finally, HC Wainwright raised MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Friday, August 15th.

MiNK Therapeutics Stock Up 0.1%

Shares of NASDAQ:INKT opened at $13.68 on Thursday. The firm has a market cap of $61.83 million, a P/E ratio of -4.75 and a beta of 0.33. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00. The company’s 50-day moving average price is $14.38 and its two-hundred day moving average price is $12.77.

MiNK Therapeutics (NASDAQ:INKT) last announced its earnings results on Thursday, August 14th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.51). As a group, equities analysts predict that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.